BioMarin Pharmaceutical Inc. with ticker code (BMRN) now have 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $140.00 and $72.00 with the average target price sitting at $108.03. Now with the previous closing price of $85.02 this would indicate that there is a potential upside of 27.1%. The 50 day MA is $82.67 while the 200 day moving average is $87.38. The total market capitalization for the company now stands at 15.98B. The stock price is currently at: $84.15 USD
The potential market cap would be $20,302,831,635 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 79.39, revenue per share of $13.12 and a 1.77% return on assets.
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies that address the root cause of genetic conditions. The Company’s portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin’s commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company’s clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.
